Use of Thalidomide for Alzheimers Disease Treatment and Prevention
OwnerYong Shen, Marwan N. SABBAGHinventors
Life of this patent
Estimating the term…
Abstract
β-secretase (BACE) is a biomarker for MCI and Alzheimer's disease. BACE1 protein level and the enzymatic activity level increase in the brain, and in the CSF in AD and MCI patients. Increased BACE1 levels in CSF are related to neuronal death and synaptic damages, which contribute to AD-related cognitive deficits. BACE1 inhibitors may be used as therapeutic compounds for clinical use for the disease treatment and prevention. Use of Thalidomide, an effective BACE1 inhibitor, reduces the BACE1 enzymetic activity and protein levels, and the Aβ production that marks the neurodegenerative progression associated with AD.
Claims17
A method for the treatment of cognitive deficit diseases in a mammal, comprising the step of administering a therapeutically effective amount of Thalidomide or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof to the mammal.
A kit used to treat cognitive deficit diseases comprising pharmaceutical composition and dosage form of Thalidomide or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof.
A method for the prevention of Alzheimer's disease in a mammal comprising administering an effective amount of Thalidomide or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof to the mammal.
Dependencies are inferred from the claim text.